Navigation Links
Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Date:6/16/2008

these new approaches into clinical medicine."

"We are gratified for the opportunity to work jointly with Fox Chase Cancer Center and Olympus Corporation to develop the first clinical applications of our fluorescence molecular imaging technology platforms," said Kirtland Poss, President and CEO of VisEn Medical. "This program is a major step forward in VisEn Medical's central mission, which is to lead the development and commercialization of fluorescence in vivo imaging technologies in a range of translational applications from research through clinical medicine, enabling substantial benefits for researchers, pharmaceutical companies, doctors and patients."

Both Dr. Seiden and Mr. Poss noted the contributions to the project by Olympus Medical Systems Corp. "We are pleased to receive the system support from Olympus Medical Systems Corp. through their provision of these novel fluorescence imaging systems into the program," said Mr. Poss. "These advances will help open up new opportunities for more effective and efficient cancer detection, surgery and treatment."

The ProSense(R) Activatable Imaging Agent platform was developed to provide in vivo readouts of some of the key protease activities known to underlie disease states in oncology, inflammation, and cardiovascular disease. A pre-clinical version of ProSense is currently being used by leading academic institutions and pharmaceutical customers worldwide to image disease-related in vivo protease profiles in pre-clinical research and drug development. The IND program and the planned Phase I clinical trials are designed to translate the benefits of ProSense into humans, as well as to further develop the multi-channel white light and near infrared fluorescence laparoscopic imaging systems used in collecting and analyzing fused images in real time in the operating room. The planned trial is also designed to gather safety and imaging data for the agent, which will be administered systemically, and to
'/>"/>

SOURCE VisEn Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
2. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
5. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
6. Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
7. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
8. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
9. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
10. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
11. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... AUSTIN, Texas , Oct. 17, 2014  Hanger, ... it plans to report its results of operations for ... 6, 2014 after the market closes.  A conference call ... 9:00 a.m., ET, on Friday, November 7, 2014. Those ... be available until Friday, November 14, 2014 by dialing ...
(Date:10/17/2014)... Oct. 17, 2014 UBM Medica US announces that ... online community and information resource for neurologists and other healthcare ... Alzheimer disease , with discussions of the latest developments ... million Americans have Parkinson disease , more than the total ... Lou Gehrig disease. Diagnosis can be difficult because there ...
(Date:10/17/2014)... , Oct. 17, 2014 Research ... "Research and Development Prospect of China Dialysis ... Based on the 2013 version, this ... policies about dialysis industry and the relevant effect ... about dialysis industry segmentations. Moreover, it analyzes Chinese ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... 31st European Cystic Fibrosis Conference -, SOUTH ... /PRNewswire/,-- PTC Therapeutics, Inc. (PTC) today announced promising ... fibrosis (CF). Results from an Israeli Phase 2a,extension ... in adult,patients with nonsense-mutation-mediated CF demonstrated statistically,significant improvements ...
... Data from Positive Phase 2a Trial, WALTHAM, ... ) today announced that based on feedback from ... initiate a Phase 2b clinical,trial of RG2417, an ... later this year. This will be a multi-center, ...
Cached Medicine Technology:PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 2PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 3PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 4PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 5Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 2Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 3Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 4Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 5
(Date:10/20/2014)... 20, 2014 It’s hard to imagine what ... and vulnerable children around the world, it’s a reality. And ... many children are forced to walk barefoot on rocky terrain ... or play with their friends. , Buckner International's ... Air1 Radio in October to encourage support for Air1 ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury ... the greater Phoenix area and across Arizona reports record ... catastrophic automobile accidents. Statistics have indicated a steady increase ... As such, Hastings and Hastings has seen a steady ... who have been injured through no fault of their ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s ... for long evening dresses . All the company’s ... the current discount is up to 66 percent off. ... in the fashion field. Its dress specialists are striving ... various parts of the world. All the company’s items ...
(Date:10/19/2014)... is a systemic disease that causes inflammation in ... affected members of the ancient Egyptian royal families. ... & Rheumatology , a journal of the American ... instead a degenerative spinal condition called diffuse idiopathic ... the 18th to early 20th Dynasties. , ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... ... availability of its new Alterian Content Manager, Professional Edition. This product ... collaboration with Microsoft, together into one package for partners and customers ... Content Manager is the Content Management System (CMS) behind more than ...
... ... selection of deals for Mother’s Day. Experienced experts research the internet to provide the ... as laptops, HDTVs, Father’s Day and graduation. , ... (PRWEB) April 26, 2010 -- Mother’s Day Deals ...
... ... is extremely difficult to identify what level of degradation has taken place caused by factors ... used racking must recognise that any uncertainty presents serious safety risks that they can be ... ...
... ... business Internet video advertising program that can deliver first page Internet search ... web page search engine optimization. The Site Steering small business advertising program ... using a proprietary method to distribute the video to the Internet. ...
... Using routine data from electronic patient records to select individuals ... all adults aged between 40 and 74 years of age, ... cheaper to run, according to research published on bmj.com ... in the last twenty years, heart problems remain the leading ...
... ... $150,000 Contribution to Assist the Haitian People, , ... Palm Beach, FL (Vocus) April 25, 2010 -- The ... and improves public policy by communicating pharmacy and suppliers’ work to improve lives and ...
Cached Medicine News:Health News:Alterian Releases Professional Edition of its Content Manager Technology, Offering Partners and Clients an Even Faster Time-to-Live for Their Websites 2Health News:Alterian Releases Professional Edition of its Content Manager Technology, Offering Partners and Clients an Even Faster Time-to-Live for Their Websites 3Health News:Alterian Releases Professional Edition of its Content Manager Technology, Offering Partners and Clients an Even Faster Time-to-Live for Their Websites 4Health News:Expert Approved: FatWallet Guides Mother's Day Shoppers to the Best Deals Online 2Health News:Warning Over Dangers of Used Racking Issued By Thistle Systems 2Health News:Warning Over Dangers of Used Racking Issued By Thistle Systems 3Health News:Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days 2Health News:Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days 3Health News:Selecting high-risk patients for heart screening 2Health News:NACDS' Anderson Says Retailers and Suppliers' “Health and Wellness Renaissance” is Creating a “Historic, Watershed Moment” 2Health News:NACDS' Anderson Says Retailers and Suppliers' “Health and Wellness Renaissance” is Creating a “Historic, Watershed Moment” 3Health News:NACDS' Anderson Says Retailers and Suppliers' “Health and Wellness Renaissance” is Creating a “Historic, Watershed Moment” 4
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... uses a classical distance-independent measuring principle which ... The size of the mire image is ... and the measured object; 2. The resulting ... the Ophthalmometer and the measured object; 3. ...
Medicine Products: